A pilot clinical trial to evaluate a novel time-to-positivity assay to measure the effectiveness of antibiotic therapy for septic patients in intensive care

Journal of Critical Care

Volumn 27, Issue 3, 2012, Pages 320.e1-320.e5

  Jerwood, Susannah ^a   Hankins, Matthew ^b   Cohen, Jon ^a,b  

^a Worthing Hospital   (United Kingdom)

^b BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antibiotics; Clinical trial; Sepsis; Treatment

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; APACHE; ARTICLE; ASSAY; BACTERIAL STRAIN; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PILOT STUDY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; SCORING SYSTEM; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT; TIME TO POSITIVITY ASSAY; TREATMENT OUTCOME;

EID: 84861184174     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2011.06.009     Document Type: Article

References (12)

1. Garnacho-Montero J., Ortiz-Leyba C., Herrera-Melero I., et al. Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J Antimicrob Chemother 2008, 61:436-441.
2. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
3. Ibrahim E.H., Sherman G., Ward S., et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146-155.
4. Kaltsas P., Want S., Cohen J. Development of a time to positivity assay as a tool in the antibiotic management of septic patients. Clin Microbiol Infect 2005, 11:109-114.
5. Bone R.C., Balk R.A., Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655.
6. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving Sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34:17-60.
7. Leroy O., Meybeck A., d'Escrivan T., et al. Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia. Intensive Care Med 2003, 29:2170-2173.
8. Frei C.R., Burgess D.S. Continuous infusion β-lactams for intensive care unit pulmonary infections. Clin Microbiol Infect 2005, 11:418-421.
9. Taccone F.S., Laterre P.-F., Dugernier T., et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010, 14:R126.
10. Roberts J.A., Ulldemolins M., Roberts M.S., et al. Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010, 36:332-339.
11. Reller L.B. The serum bactericidal test. Rev Infect Dis 1986, 8:803-808.
12. Lodise T.P., Drusano G.L. Pharmacokinetics and pharmacodynamics: optimal antimicrobial therapy in the intensive care unit. Crit Care Clin 2011, 27:1-18.